Remove 2020 Remove Compounding Remove Diabetes
article thumbnail

Hims & Hers Health to introduce generic Liraglutide in 2025 amid growing demand for weight-loss medications

Express Pharma

Telehealth firm Hims & Hers Health said on Monday it plans to bring a generic version of Novo Nordisk’s diabetes drug, liraglutide, to its platform in 2025. It results in less weight loss on average than Novo’s newer in-demand Wegovy, which launched in 2020 and was approved in 2022 for adolescents aged 12 and older.

article thumbnail

Study Reveals Gaps in GINA Guideline Adherence for Asthma Treatment

Pharmacy Times

2019;380:2020-2030. Global Initiative for Asthma. Accessed June 9, 2025. Beasley R, Holliday M, Reddell HK, et al. Controlled trial of budesonide-formoterol as needed for mild asthma. N Engl J Med.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

You Shall Not Pass: Pharmacist Review of Drug-Herb Interactions in Cancer Treatment

Pharmacy Times

Data collection spanned January 2020 to March 2023. This study examines herbal supplement prevalence, pharmacist interventions, and their impact on oncology treatment safety. Materials and Methods A survey-based observational study was conducted at the UC Davis Comprehensive Cancer Center.

article thumbnail

Because Ned Said: New Technology Helps Prevent Opioid Overdose

Pharmacy Times

trillion economic impact in 2020. trillion economic impact in 2020. trillion economic impact in 2020. LIMITX technology, developed by Abuse Deterrent Pharma and Acura Pharmaceuticals, controls drug release to reduce overdose risk.

article thumbnail

Pharmacy Policy Updates for June 2025

Pharmacy Times

The first one was introduced on September 13, 2020, near the end of Trump’s first term, but was shut down by a federal judge due to the administration’s failure to comply with the proper implementation processes.

article thumbnail

Breaking New Ground in Migraine Prevention: Eptinezumab-jjmr

Pharmacy Times

On February 21, 2020, the FDA approved eptinezumab-jjmr (Vyepti; Lundbeck) as the first intravenous migraine preventative treatment for adults. Pharmacists are essential in managing access, patient education, and monitoring outcomes, ensuring adherence and addressing administrative challenges.

article thumbnail

NHC Submits Comments on CMS Draft Guidance for IPAY 2028

Putting Patients First Blog

At the same time, the NHC recommends that CMS avoid incorporating the MFP into ASP calculations, as doing so could depress reimbursement rates across both Medicare and commercial markets, compounding access risks and straining provider viability. Report to the Congress: Medicare and the Health Care Delivery System , June 2020.